Foghorn Therapeutics (FHTX) financial statements
Foghorn Therapeutics reported revenue of $31M in fiscal 2025, up 135.1% a year over 5 years.
Net income was -$74M.
Free cash flow was -$86M.
The diluted share count rose 1402% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Foghorn Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $430,000 | $1M | $19M | $34M | $23M | $31M |
| Research and development | $44M | $58M | $80M | $106M | $110M | $95M | $85M |
| Selling, general and admin | $7M | $11M | $22M | $31M | $32M | $28M | $28M |
| Operating income | -$51M | -$69M | -$101M | -$117M | -$108M | -$103M | -$86M |
| Interest expense | $540,000 | $979,000 | $2M | — | — | — | — |
| Pre-tax income | — | — | — | -$109M | -$94M | -$87M | — |
| Income tax | $0 | $0 | — | $0 | $4M | $0 | $0 |
| Net income | -$51M | -$69M | -$101M | -$109M | -$98M | -$87M | -$74M |
| EPS (diluted) | -$12.20 | -$6.23 | -$2.73 | -$2.62 | -$2.34 | -$1.58 | -$1.18 |
| Diluted shares | 4M | 11M | 37M | 42M | 42M | 55M | 63M |
| Operating margin | — | -15937.4% | -7637.1% | -609.2% | -315.9% | -454.3% | -279.5% |
| Net margin | — | -16000.0% | -7681.6% | -566.3% | -288.2% | -383.2% | -240.3% |
Balance sheet
Fiscal years, from Foghorn Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $15M | $93M | $101M | $52M | $80M | $55M | $81M |
| Total current assets | $17M | $191M | $460M | $351M | $240M | $250M | $163M |
| Property, plant and equipment | $3M | $20M | $18M | $15M | $13M | $10M | $2M |
| Total assets | $22M | $256M | $520M | $405M | $286M | $284M | $198M |
| Total current liabilities | $13M | $19M | $49M | $55M | $58M | $67M | $60M |
| Long-term debt | $11M | $20M | $0 | — | — | — | — |
| Total liabilities | $24M | $109M | $423M | $405M | $363M | $330M | $307M |
| Shareholders' equity | -$88M | $146M | $97M | $112,000 | -$77M | -$46M | -$108M |
| Net debt | $131,000 | -$73M | -$101M | -$52M | -$80M | -$55M | -$81M |
Cash flow
Fiscal years, from Foghorn Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$46M | -$31M | -$50M | $194M | -$118M | -$100M | -$86M |
| Capital spending | $968,000 | $16M | $3M | $1M | $1M | $906,000 | $50,000 |
| Free cash flow | -$47M | -$47M | -$54M | $192M | -$119M | -$101M | -$86M |
| Stock-based compensation | $2M | $3M | $8M | $14M | $16M | $12M | $10M |
| Free cash flow margin | — | -11039.3% | -4060.9% | 1000.6% | -349.4% | -448.2% | -278.7% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for FHTX.
Open FHTX in InvestinglyQuestions
What was Foghorn Therapeutics's revenue in 2025?
$31M in fiscal 2025, from its 10-K filing.
How much free cash flow does Foghorn Therapeutics generate?
-$86M in fiscal 2025 (operating cash flow minus capital spending).
From Foghorn Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.